Day 1 - Monday, 28 September 2020
Meeting category
Date(s)
28 Sep 2020 - 30 Sep 2020
Organizer
Titanium Level Support
Sponsor logos
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020
Related Enduring Materials
Enduring Materials
Preliminary Program
Opening - 10:00
10:00 EDT
Opening Remarks
Session 1: COVID-19 Session - 10:10
Mohammed Lamorde, FRCP, PhD
10:10 EDT
Emerging infections and Biosecurity
Infectious Diseases Institute, Makerere University College Of Health Sciences, Uganda, Africa
10:30 EDT
Clinical treatment of COVID-19
10:50 EDT
Role of Pharmacology of selection COVID candidates
11:10 EDT
FDA perspective on COVID-19
11:30 EDT
Faculty Discussion
Session 2: Abstracts Session - 12:30
12:30 EDT
Oral Abstract Presentation session
Steady-State Plasma TFV/FTC Among Adolescent Transgender Men and Women Receiving Directly Observed Daily TDF/FTC #01
Jenna Yager, University of Colorado, USA
Plasma and Breastmilk Pharmacokinetics of Tenofovir Using Dried Blood and Breast Milk Spots in HIV Infected Postpartum Women in Uganda #02
Letisha Najjemba, Infectious Disease Institute, Uganda
Time Course of Tenofovir-Diphosphate Carryover in DBS Following TDF to TAF Switch #03
Kristina Brooks, University of Colorado, USA
13:00 EDT
Live Q&A with Abstract Presenters
13:15 EDT
Oral Poster Presentations
TFVdp/FTCtp Concentrations in Rectal Samples: No Correlation Between Epithelial Cells Collected by Cytobrush and Isolated CD4+ Cells #04
Mackenzie Cottrell, UNC Eshelman School of Pharmacy, USA
Mechanistic Modelling for the Quantitative Evaluation #05
Fazila Bunglawala, University of Liverpool, UK
Intracellular EFdA Pharmacology Differs Between Species: Implications for Preclinical Study Design #06
Mackenzie Cottrell, UNC Eshelman School of Pharmacy, USA
Inflammation Affects Antiretrovirals Plasma and Intracellular Exposure #07
Micol Ferrara, Ospedale Amedeo Di Savoia, Italy
13:35 EDT
Live Q&A with Abstract Presenters
13:45 EDT
End of first day
DAY 2 - Tuesday, 29 September 2020
Session 3: Management of New Antivirals - 10:00
Marta Boffito, MD, PhD, FRCP, MBA
10:00 EDT
Pharmacology of bNABs
10:20 EDT
Clinical Pharmacology Long Acting ARVs
Chelsea and Westminster Hospital NHS Foundation Trust; Imperial College London; United Kingdom
10:40 EDT
Development of Novel Formulations/Devices
11:00 EDT
Faculty Discussion
Session 4: Abstracts Session - 12:00
12:00 EDT
Oral Abstract Presentations - Population PK
Population Pharmacokinetics of HIV-Specific Broadly Monoclonal Neutralizing Long-Acting Antibody, VRC01LS, in Term Infants #08
Jincheng Yang, University of California San Diego, USA
In-Silico Prediction of Intramuscular Long-Acting Rilpivirine in Liver Impairment With PBPK Models #09
Nicolas Cottura, University of Liverpool, UK
12:30 EDT
Live Q&A with Abstract Presenters
12:25 EDT
Oral Poster Presentations
Lack of a Pharmacokinetic (PK) Interaction Between HIV-1 Maturation Inhibitor (MI) GSK3640254 (GSK’254) and Oral Contraceptive (OC) Ethinyl Estradiol (EE)/Levonorgestrel Pbpk Models #10
-
Lack of a Pharmacokinetic (PK) Interaction Between HIV-1 Maturation Inhibitor (MI) GSK3640254 and Dolutegravir #11
-
Open-Label, Drug-Drug Interaction Study between HIV-1 Maturation Inhibitor (MI) GSK3640254 and Tenofovir Alafenamide (TAF)/Emtricitabine (FTC) in Healthy Participants #12
Teodora Pene Dumitrescu, Glaxosmithkline, USA
Antiretroviral Drug-drug Interaction (DDI) Profile of Long-acting Cabotegravir and Rilpivirine #13
Parul Patel, ViiV Healthcare, USA
Fostemsavir Drug-Drug Interaction Profile, an Attachment Inhibitor and Oral Prodrug of Temsavir, for Patients With Multidrug Resistant HIV-1 Infection #14
Katy Moore, ViiV Healthcare, USA
Pharmacokinetics, Safety, and Tolerability of Single- and Multiple Ascending Doses of JNJ-64417184, a Non-Nucleoside Inhibitor of Respiratory Syncytial Virus Polymerase, in Healthy Volunteers #15
Mina Pastagia, Janssen Biopharma, USA
Single-Ascending Dose (SAD) Pharmacokinetics of Hepatitis B Virus (HBV)-Specific JNJ-73763989 in Non-Japanese and Japanese Healthy Volunteers (HV) #16
Thomas Kakuda, Janssen Biopharma, USA
Effect of Multiple-Dose Itraconazole on the Pharmacokinetics of Single-Dose JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Volunteers #17
Joris Vandenbossche, Janssen Biopharma, USA
13:00 EDT
Live Q&A with Abstract Presenters
13:15 EDT
End of second day
Online Networking Opportunities & E-Poster Viewing
DAY 3 - Wednesday, 30 September 2020
Session 5: Topic for Discussion - 10:00
10:00 EDT
Perspectives on the Use of Endogenous Biomarkers to Assess Transporter Mediated Drug-Drug Interactions (DDIs)
10:25 EDT
Role of herbal in DDIs
10:50 EDT
Faculty discussion
11:05 EDT
Virtual Coffee Break | Meet Your Colleagues
Session 6: Abstracts Session - 11:35
11:35 EDT
Oral Abstract Presentations - Special Populations - Pediatrics
Impact of CYP2B6 Genotype, TB Therapy and Formulation on Efavirenz Pharmacokinetics in Infants and Children Under 40 Months of Age #18
Mina Nikanjam, University of California San Diego, USA
A Population Pharmacokinetic Analysis Assessing the Exposure of Raltegravir Once-Daily 1200mg in Pregnant Women Living With HIV #19
Vera Bukkems, Radboudumc, Netherlands
Comparison of Relative Bioavailability of TIVICAY Neonatal Liquid Formulations to Pediatric Dispersible Tablets #20
Rajendra Singh, Glaxosmithkline, USA
12:05 EDT
Live Q&A with Abstract Presenters
12:20 EDT
Oral Poster Presentations - Special Populations
Ledipasvir PK-PD (Pharmacokinetics - Pharmacodynamics): Relationship between drug exposure and sustained virologic response rates in a cohort of patientsRelationship Between Drug Exposure and Sustained Virologic Response Rates in a Cohort of Patients #21
Omar Elsherif, Queen Elizabeth Hospital Birmingham, UK
Exploring the Role of Age in Transporter-Related Drug-Drug Interactions #22
Hannah Kinvig, University of Liverpool, UK
Genetic Associations With Weight Gain Among South Africans Who Initiated Dolutegravir- and Tenofovir-Containing Regimens in the ADVANCE Study #23
Zinhle Cindi, University of Cape Town, South Africa
Rifabutin Pharmacokinetics and Safety Among TB/HIV Coinfected Young Children Receiving Lopinavir #24
Holly Rawizza, Brigham and Women's Hospital, USA
Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers: A Preliminary #25
Jomy George, National Institutes of Health, USA
12:45 EDT
Live Q&A with Abstract Presenters
12:55 EDT
Closure - Best of Abstracts Awards
13:00 EDT
End of the Virtual Workshop
Overview
Welcome
Understanding the clinical pharmacology of antiviral therapy is pivotal to designing optimal treatment and prevention strategies. The International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs gathers leading experts to discuss all aspects of the optimal use of antiviral therapy including drug-drug interactions, pharmacokinetics of investigational and existing drugs, pharmacodynamics, drug dosing in special populations, post-marketing surveillance, and regulatory considerations.
Program Chairs 2020
General Information
COVID-19 Update
In light of the COVID-19 pandemic, the International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2020 was held as a completely virtual meeting so that the program would be delivered safely and conveniently.
To deliver a highly educational, interactive, and enjoyable experience, the program was spread over three days, from 28 to 30 September 2020. Ample time was reserved for discussion and virtual networking opportunities. We offered delegates a special reduced fee to participate in this online program.
We are available to answer any questions or concerns that you may have about your participation at the International Workshop on Clinical Pharmacology on HIV, Hepatitis, and Other Antiviral Drugs 2020. For more information, please contact Victoria Sarasola at victoria@amededu.com.
To stay updated on developments in relation to the International Workshop on Clinical Pharmacology on HIV, Hepatitis, and Other Antiviral Drugs, make sure that you are signed up for our newsletter.
To deliver a highly educational, interactive, and enjoyable experience, the program was spread over three days, from 28 to 30 September 2020. Ample time was reserved for discussion and virtual networking opportunities. We offered delegates a special reduced fee to participate in this online program.
We are available to answer any questions or concerns that you may have about your participation at the International Workshop on Clinical Pharmacology on HIV, Hepatitis, and Other Antiviral Drugs 2020. For more information, please contact Victoria Sarasola at victoria@amededu.com.
To stay updated on developments in relation to the International Workshop on Clinical Pharmacology on HIV, Hepatitis, and Other Antiviral Drugs, make sure that you are signed up for our newsletter.
Unique Features
The International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs will provide a platform for discussions on current topics fundamental to the optimal use of antiviral therapy including drug-drug interactions, pharmacokinetics of investigational agents and existing drugs, pharmacodynamics, drug dosing in special populations, postmarketing surveillance, and regulatory considerations.
Who Should Attend?
- Clinical pharmacologists
- Pharmacists
- Clinicians/ researchers
- Industry representatives
- Regulatory scientists
- Government representatives
- Post-graduate students
- Others involved in the clinical pharmacology of antiviral therapy
- Pharmacists
- Clinicians/ researchers
- Industry representatives
- Regulatory scientists
- Government representatives
- Post-graduate students
- Others involved in the clinical pharmacology of antiviral therapy
Meeting Objectives
This meeting aims to:
- To gather experts involved in clinical pharmacology from different disciplines in an interactive workshop setting
- To provide a platform for presentation and discussion of the latest developments in the field
- To share information on ongoing pharmacological studies
- To translate new data to treatment guidelines
- To stimulate discussion and consensus on best practices
- To gather experts involved in clinical pharmacology from different disciplines in an interactive workshop setting
- To provide a platform for presentation and discussion of the latest developments in the field
- To share information on ongoing pharmacological studies
- To translate new data to treatment guidelines
- To stimulate discussion and consensus on best practices
Learning Objectives
After participating in this activity, participants will be able to:
- Outline new developments in antiviral therapy
- Identify treatment options for hepatitis-infected patients
- Reflect on the role of pharmacogenomics in clinical management
- Describe the various pharmacological parameters of integrase inhibitors
- Outline new developments in antiviral therapy
- Identify treatment options for hepatitis-infected patients
- Reflect on the role of pharmacogenomics in clinical management
- Describe the various pharmacological parameters of integrase inhibitors
Practical Information
Accreditation
An application has been made to the UEMS EACCME® for the CME accreditation of this event.
Certificate of Attendance
A certificate of attendance was sent to participants that successfully completed the program and post-meeting survey.
Language
The official language of the workshop was English. Translation was not provided.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.
Liability and Insurance
By registering for the workshop participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official workshop sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided that the speaker has given permission to do so.
Committees
The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts.
Scientific Committee
The members of Scientific Committee are hand-picked by the Organizing Committee and the conference secretariat based on their significant contributions and commitment to the field. They assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.
Academic Advisory Board
- David Back, PhD - University of Liverpool, United Kingdom
- Terrence Blaschke, MD - Stanford University School of Medicine, United States
- Charles Boucher, PhD - Erasmus Medical Center, the Netherlands
- David Burger, MD, PhD - Radboud University Medical Center, the Netherlands
- Giovanni Di Perri, MD, PhD - University of Torino, Italy
- Courtney Fletcher, PharmD - University of Nebraska Medical Center, United States
- Charles Flexner, MD - Johns Hopkins University, United States
- Angela Kashuba, PharmD - University of North Carolina at Chapel Hill, United States
- Jürgen Rockstroh, MD - University of Bonn, Germany
- Jonathan Schapiro, MD - Sheba Medical Centre, Israel
Industry Liaison Board
The Industry Liaison Board, consisting of leading medical scientists of the pharmaceutical industry, is asked to give input and suggestions that help the Organizing Committee in planning the workshop and providing support on topics of interest and innovative suggestions to optimize audience participation. The Industry Liaison Board assists the Organizing Committee by suggesting the most current and critical topics to bring the audience up-to-date on the most current research in the pharmaceutical industry in related disciplines.
- Timonthy Eley - Arbutus
- Yash Gandhi - BMS
- Daria Hazuda - Merck
- Thomas Kakuda - Alios BioPharma
- Charles LaPorte - Janssen Biologics
- Wei Liu - AbbVie
- Anita Mathias - Gilead Sciences
- Parul Patel - ViiV Healthcare
- Manoli Vourvahis - Pfizer
Support
Endorsers
Endorsers
Language
Related Programs
